Immune effects of CDK4/6 inhibitors in patients with HR⁺/HER2^- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.

It is interesting to note that only in R patients, the decrease in Tregs observed during treatment was mainly due to a decrease in the effector Treg cells ( p <0.0001; Figure 2 ), while in the resting and non-activated Treg subsets there was a slightly significant downregulation (Supplementary Figure 3).

also in 1,750 other papers